HLB Panagene Co., Ltd. (KOSDAQ:046210)

Market Cap	96.63B +10.7%
Revenue (ttm)	15.05B +14.0%
Net Income	-3.13B
EPS	-70.00
Shares Out	45.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	138,544
Average Volume	246,611
Open	2,200.00
Previous Close	2,180.00
Day's Range	2,105.00 - 2,200.00
52-Week Range	1,535.00 - 2,940.00
Beta	0.03
RSI	40.64
Earnings Date	Mar 20, 2026

About HLB Panagene

HLB Panagene Co., Ltd. manufactures and sells genetic diagnostic products in South Korea and internationally. It offers PANAMutyper, which detects small amount of mutation with high sensitivity and genotypes multiple mutations for oncology liquid biopsy; PNAClamp, a PNA-based PCR clamping that detects and amplifies only the mutated target DNA sequence for oncology tissue biopsy; PANA RealTyper, a PNA probe-based fluorescence melting curve analysis tool that detects mutation and distinguishes multiple SNPs adjacent for infectious diseases; PANA ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1976
• Employees: 82
• Stock Exchange: KOSDAQ
• Ticker Symbol: 046210

Financial Performance

In 2025, HLB Panagene's revenue was 15.05 billion, an increase of 14.04% compared to the previous year's 13.20 billion. Losses were -3.13 billion, 60.8% more than in 2024.